Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

December 12, 2023

https://www.globenewswire.com/news-release/2023/12/12/2794338/0/en/Harpoon-Therapeutics-Presents-HPN217-Phase-1-Clinical-Data-in-Relapsed-Refractory-Multiple-Myeloma-RRMM-at-ASH-2023-and-Announces-Selection-of-Recommended-Phase-2-Dose-RP2D.html

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy

Read more at globenewswire.com

Related news for (HARP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.